ELF score ≥9.8 indicates advanced hepatic fibrosis and is influenced by age, steatosis and histological activity

Liver International

Volumn 35, Issue 6, 2015, Pages 1673-1681

  Fagan, Kevin J ^a,b   Pretorius, Carel J ^b,c   Horsfall, Leigh U ^a,b   Irvine, Katharine M ^b   Wilgen, Urs ^b,c   Choi, Kihoon ^b   Fletcher, Linda M ^a,b   Tate, Jill ^c   Melino, Michelle ^b   Nusrat, Sharmin ^b   Miller, Gregory C ^b   Clouston, Andrew D ^b   Ballard, Emma ^d   O'Rourke, Peter ^d   Lampe, Guy ^a   Ungerer, Jacobus P J ^c   Powell, Elizabeth E ^a,b  

^a PRINCESS ALEXANDRA HOSPITAL   (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

^c Pathology Queensland   (Australia)

^d QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

Author keywords

Biomarker; Cirrhosis; Collagen proportional area; Liver; Non alcoholic fatty liver disease

Indexed keywords

TISSUE INHIBITOR OF METALLOPROTEINASE 1; BIOLOGICAL MARKER; COLLAGEN;

ADULT; AGE; ALCOHOL CONSUMPTION; ARTICLE; BODY MASS; CLINICAL FEATURE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIGESTIVE SYSTEM DISEASE ASSESSMENT; DIGITAL SLIDE SCANNER; DISEASE SEVERITY; DISSE SPACE; ENHANCED LIVER FIBROSIS TEST; FATTY LIVER; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LIVER BIOPSY; LIVER FIBROSIS; LIVER HISTOLOGY; LIVER PARENCHYMA; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NON INVASIVE PROCEDURE; OBESITY; PORTAL VEIN; PREDICTIVE VALUE; SENSITIVITY AND SPECIFICITY; BIOPSY; BLOOD; COMPLICATION; LIVER; LIVER CIRRHOSIS; MULTIVARIATE ANALYSIS; NONALCOHOLIC FATTY LIVER; PATHOLOGY; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX;

AGE FACTORS; BIOMARKERS; BIOPSY; COLLAGEN; FEMALE; HUMANS; LIVER; LIVER CIRRHOSIS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NON-ALCOHOLIC FATTY LIVER DISEASE; OBESITY; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX;

EID: 84929132450     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.12760     Document Type: Article

References (36)

1. Statistics ABO. Australian Health Survey: Biomedical Results for Chronic Diseases, 2011-12, 2013. Available at http://www.abs.gov.au/ausstats/abs@.nsf/Lookup/4364.0.55.005Chapter5002011-12. Accessed 5 August 2013.
2. Kemp W, Roberts S. FibroScan(R) and transient elastography. Aust Fam Physician 2013; 42: 468-71.
3. Adams LA, George J, Bugianesi E, et al. Complex non-invasive fibrosis models are more accurate than simple models in non-alcoholic fatty liver disease. J Gastroenterol Hepatol 2011; 26: 1536-43.
4. Guha IN, Parkes J, Roderick P, et al. Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: validating the European liver fibrosis panel and exploring simple markers. Hepatology 2008; 47: 455-60.
5. Rosenberg WM, Voelker M, Thiel R, et al. Serum markers detect the presence of liver fibrosis: a cohort study. Gastroenterology 2004; 127: 1704-13.
6. Mayo MJ, Parkes J, Adams-Huet B, et al. Prediction of clinical outcomes in primary biliary cirrhosis by serum enhanced liver fibrosis assay. Hepatology 2008; 48: 1549-57.
7. Kim BK, Kim HS, Park JY, et al. Prospective validation of ELF test in comparison with Fibroscan and FibroTest to predict liver fibrosis in Asian subjects with chronic hepatitis B. PLoS ONE 2012; 7: e41964.
8. Parkes J, Guha IN, Roderick P, et al. Enhanced liver fibrosis (ELF) test accurately identifies liver fibrosis in patients with chronic hepatitis C. J Viral Hepat 2011; 18: 23-31.
9. Nobili V, Parkes J, Bottazzo G, et al. Performance of ELF serum markers in predicting fibrosis stage in pediatric non-alcoholic fatty liver disease. Gastroenterology 2009; 136: 160-7.
10. Guechot J, Trocme C, Renversez JC, Sturm N, Zarski JP; Group AHEFS. Independent validation of the Enhanced Liver Fibrosis (ELF) score in the ANRS HC EP 23 Fibrostar cohort of patients with chronic hepatitis C. Clin Chem Lab Med 2012; 50: 693-9.
11. Fernandes FF, Ferraz ML, Andrade LE, et al. Enhanced liver fibrosis panel as a predictor of liver fibrosis in chronic hepatitis C patients. J Clin Gastroenterol 2015; 49: 235-41.
12. Lichtinghagen R, Pietsch D, Bantel H, et al. The Enhanced Liver Fibrosis (ELF) score: normal values, influence factors and proposed cut-off values. J Hepatol 2013; 59: 236-42.
13. Wahl K, Rosenberg W, Vaske B, et al. Biopsy-controlled liver fibrosis staging using the enhanced liver fibrosis (ELF) score compared to transient elastography. PLoS ONE 2012; 7: e51906.
14. Friedrich-Rust M, Rosenberg W, Parkes J, et al. Comparison of ELF, FibroTest and FibroScan for the non-invasive assessment of liver fibrosis. BMC Gastroenterol 2010; 10: 103.
15. Germani G, Burroughs AK, Dhillon AP. The relationship between liver disease stage and liver fibrosis: a tangled web. Histopathology 2010; 57: 773-84.
16. Huang Y, de Boer WB, Adams LA, et al. Image analysis of liver collagen using sirius red is more accurate and correlates better with serum fibrosis markers than trichrome. Liver Int 2013; 33: 1249-56.
17. Siemens Healthcare Diagnostics Inc. ELF Test. Tarrytown, NY: Bayer Corp Library, 2011; 1-10.
18. Bedossa PZ, Zafrani ES, Poynard T, et al. Intraobserver and interobserver variations in liver-biopsy interpretation in patients with chronic hepatitis-C. Hepatology 1994; 20: 15-20.
19. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 1996; 24: 289-93.
20. Kleiner DE, Brunt EM, van Natta M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005; 41: 1313-21.
21. Calvaruso V, Burroughs AK, Standish R, et al. Computer-assisted image analysis of liver collagen: relationship to Ishak scoring and hepatic venous pressure gradient. Hepatology 2009; 49: 1236-44.
22. Powell EE, Ali A, Clouston AD, et al. Steatosis is a cofactor in liver injury in hemochromatosis. Gastroenterology 2005; 129: 1937-43.
23. Clouston AD, Jonsson JR, Powell EE. Steatosis as a cofactor in other liver diseases: hepatitis C virus, alcohol, hemochromatosis, and others. Clin Liver Dis 2007; 11: 173-89.
24. Leandro G, Mangia A, Hui J, et al. Relationship between steatosis, inflammation, and fibrosis in chronic hepatitis C: a meta-analysis of individual patient data. Gastroenterology 2006; 130: 1636-42.
25. Huang Y, de Boer WB, Adams LA, et al. Image analysis of liver biopsy samples measures fibrosis and predicts clinical outcome. J Hepatol 2014; 61: 22-7.
26. Parkes J, Roderick P, Harris S, et al. Enhanced liver fibrosis test can predict clinical outcomes in patients with chronic liver disease. Gut 2010; 59: 1245-51.
27. Castera L, Foucher J, Bernard PH, et al. Pitfalls of liver stiffness measurement: a 5-year prospective study of 13, 369 examinations. Hepatology 2010; 51: 828-35.
28. Trembling PM, Lampertico P, Parkes J, et al. Performance of Enhanced Liver Fibrosis test and comparison with transient elastography in the identification of liver fibrosis in patients with chronic hepatitis B infection. J Viral Hepat 2014; 21: 430-8.
29. Wong GL, Chan HL, Choi PC, et al. Non-invasive algorithm of enhanced liver fibrosis and liver stiffness measurement with transient elastography for advanced liver fibrosis in chronic hepatitis B. Aliment Pharmacol Ther 2014; 39: 197-208.
30. Candore G, Caruso C, Jirillo E, Magrone T, Vasto S. Low grade inflammation as a common pathogenetic denominator in age-related diseases: novel drug targets for anti-ageing strategies and successful ageing achievement. Curr Pharm Des 2010; 16: 584-96.
31. Poynard T, Ratziu V, Charlotte F, et al. Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis C. J Hepatol 2001; 34: 730-9.
32. Poynter ME, Daynes RA. Peroxisome proliferator-activated receptor alpha activation modulates cellular redox status, represses nuclear factor-kappaB signaling, and reduces inflammatory cytokine production in aging. J Biol Chem 1998; 273: 32833-41.
33. Skoien R, Richardson MM, Jonsson JR, et al. Heterogeneity of fibrosis patterns in non-alcoholic fatty liver disease supports the presence of multiple fibrogenic pathways. Liver Int 2013; 33: 624-32.
34. Fontana RJ, Goodman ZD, Dienstag JL, et al. Relationship of serum fibrosis markers with liver fibrosis stage and collagen content in patients with advanced chronic hepatitis C. Hepatology 2008; 47: 789-98.
35. Shaheen AA, Myers RP. Diagnostic accuracy of the aspartate aminotransferase-to-platelet ratio index for the prediction of hepatitis C-related fibrosis: a systematic review. Hepatology 2007; 46: 912-21.
36. Poynard T, Lebray P, Ingiliz P, et al. Prevalence of liver fibrosis and risk factors in a general population using non-invasive biomarkers (FibroTest). BMC Gastroenterol 2010; 10: 40.